These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32253269)

  • 21. Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.
    Kettle JG; Åstrand A; Catley M; Grimster NP; Nilsson M; Su Q; Woessner R
    Expert Opin Ther Pat; 2017 Feb; 27(2):127-143. PubMed ID: 27774824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.
    Bonelli M; Kerschbaumer A; Kastrati K; Ghoreschi K; Gadina M; Heinz LX; Smolen JS; Aletaha D; O'Shea J; Laurence A
    Ann Rheum Dis; 2024 Jan; 83(2):139-160. PubMed ID: 37923366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The next step in the treatment of immune diseases: jakinibs, inhibitors of the intracellular Janus kinase].
    van de Laar MAFJ; Hoentjen F; Thio HB
    Ned Tijdschr Geneeskd; 2019 Aug; 163():. PubMed ID: 31433146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Jakinibs in systemic lupus erythematosus: progress and prospects.
    Mok CC
    Expert Opin Investig Drugs; 2019 Jan; 28(1):85-92. PubMed ID: 30462559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects.
    Flamant M; Rigaill J; Paul S; Roblin X
    Drugs; 2017 Jul; 77(10):1057-1068. PubMed ID: 28523588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs.
    Gadina M; Johnson C; Schwartz D; Bonelli M; Hasni S; Kanno Y; Changelian P; Laurence A; O'Shea JJ
    J Leukoc Biol; 2018 Sep; 104(3):499-514. PubMed ID: 29999544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies.
    Alexander M; Luo Y; Raimondi G; O'Shea JJ; Gadina M
    Pharmaceuticals (Basel); 2021 Dec; 15(1):. PubMed ID: 35056105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.
    Kettle JG; Åstrand A; Catley M; Grimster NP; Nilsson M; Su Q; Woessner R
    Expert Opin Ther Pat; 2017 Feb; 27(2):145-161. PubMed ID: 27774822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains.
    Williams NK; Bamert RS; Patel O; Wang C; Walden PM; Wilks AF; Fantino E; Rossjohn J; Lucet IS
    J Mol Biol; 2009 Mar; 387(1):219-32. PubMed ID: 19361440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
    Coskun M; Salem M; Pedersen J; Nielsen OH
    Pharmacol Res; 2013 Oct; 76():1-8. PubMed ID: 23827161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.
    Vainchenker W; Dusa A; Constantinescu SN
    Semin Cell Dev Biol; 2008 Aug; 19(4):385-93. PubMed ID: 18682296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases.
    Menet CJ
    Pharm Pat Anal; 2014 Jul; 3(4):449-66. PubMed ID: 25291316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
    Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC
    J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Advances in study on drugs targeting the JAKs/STATs passway].
    Sheng L; Li Y
    Sheng Li Ke Xue Jin Zhan; 2006 Apr; 37(2):162-5. PubMed ID: 16850627
    [No Abstract]   [Full Text] [Related]  

  • 36. Recent Advances in the Treatment of Immune-Mediated Inflammatory Diseases.
    Tas SW; Baeten DL
    Methods Mol Biol; 2016; 1371():143-55. PubMed ID: 26530799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tofacitinib ameliorates inflammation in a rat model of airway neutrophilia induced by inhaled LPS.
    Calama E; Ramis I; Domènech A; Carreño C; De Alba J; Prats N; Miralpeix M
    Pulm Pharmacol Ther; 2017 Apr; 43():60-67. PubMed ID: 28087469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?
    Liu C; Kieltyka J; Fleischmann R; Gadina M; O'Shea JJ
    Arthritis Rheumatol; 2021 Dec; 73(12):2166-2178. PubMed ID: 34180156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tofacitinib in ulcerative colitis.
    Archer TP; Moran GW; Ghosh S
    Immunotherapy; 2016 May; 8(5):495-502. PubMed ID: 27140405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.
    Danese S; Grisham M; Hodge J; Telliez JB
    Am J Physiol Gastrointest Liver Physiol; 2016 Feb; 310(3):G155-62. PubMed ID: 26608188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.